DDInter1042 DDInter1533
Leuprolide is a synthetic 9-residue peptide analogue of gonadotropin-releasing hormone (GnRH). Unlike the endogenous decapeptide GnRH, leuprolide contains a single D-amino acid (D-leucyl) residue, which helps to increase its circulating half-life from three to four minutes to approximately three hours. As a GnRH mimic, leuprolide is capable of binding to the GnRH receptor (GnRHR) and inducing downstream modulation of both gonadotropin hormone and sex steroid levels. Prolonged activation of GnRHR results in significant downregulation of sex steroid levels, which is primarily responsible for the clinical efficacy of leuprolide in diverse conditions, including advanced prostate cancer, endometriosis, and central precocious puberty.[A203126, A203132] Leuprolide was first approved in 1985 as a daily subcutaneous injection under the tradename
Promethazine, originally known as 3,277 R.P., is an N-dimethylaminopropyl derivative of [phenothiazine] that was developed in France in 1946. Promethazine antagonizes a variety of receptors, allowing it to be used for a number of indications including allergic reactions, pain, sedation, nausea, and vomiting.[A189907,A190153,A190159,A190150,A190171] Promethazine was granted FDA approval before 29 March 1951.[A190177,L4000]
Promethazine {u} (Compound) resembles {v} (Compound) Ethopropazine
Promethazine {u} may cause a moderate interaction that could exacerbate diseases when taken with {v} Propiomazine
Promethazine {u} (Compound) resembles {v} (Compound) Chlorprothixene
Promethazine {u} may cause a moderate interaction that could exacerbate diseases when taken with {v} Doxepin
Promethazine {u} (Compound) binds {v} (Gene) CALM3
Promethazine {u} (Compound) is included by {v} (Pharmacologic Class) Phenothiazines
Promethazine {u} (Compound) causes {v} (Side Effect) Decreased appetite
Promethazine {u} may cause a minor interaction that can limit clinical effects when taken with {v} Magnesium carbonate
Promethazine {u} may cause a minor interaction that can limit clinical effects when taken with {v} Metronidazole
Promethazine {u} may lead to a major life threatening interaction when taken with {v} Toremifene
Promethazine (Compound) resembles Ethopropazine (Compound)
Promethazine may cause a moderate interaction that could exacerbate diseases when taken with Propiomazine
Promethazine (Compound) resembles Chlorprothixene (Compound)
Promethazine may cause a moderate interaction that could exacerbate diseases when taken with Doxepin
Promethazine (Compound) binds CALM3 (Gene)
Promethazine (Compound) is included by Phenothiazines (Pharmacologic Class)
Promethazine (Compound) causes Decreased appetite (Side Effect)
Promethazine may cause a minor interaction that can limit clinical effects when taken with Magnesium carbonate
Promethazine may cause a minor interaction that can limit clinical effects when taken with Metronidazole
Promethazine may lead to a major life threatening interaction when taken with Toremifene